oru.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Epigenetic changes as prognostic predictors in endometrial carcinomas
Örebro University. Örebro University Hospital.
2018 (English)Conference paper, Poster (with or without abstract) (Refereed)
Abstract [en]

Objective: In Sweden, endometrial carcinoma is number five among female cancers, with 1,400 new cases per year. The diagnostic and prognostic markers for the high-risk subgroups with unfavorable prognosis are under intense debate worldwide. The aim of the present study was to address the epigenetic differences in a consecutive series of endometrial carcinomas comprising a low-risk group (FIGO-grade 1) and a high-risk group (FIGO-grade 3) with highly significant different treatment outcomes and survival rates.

Method: We used the Illumina Infinium HumanMethylation450 BeadChip to analyze the DNA methylation pattern and investigated its association with clinicopathological features important for defining the high-risk (FIGO-grade 3) and low-risk (FIGO-grade 1) groups of patients with endometrial cancer.

Results: We identified 2,224 differentially methylated CpG sites. Gene ontology analysis classified the hypomethylated genes in the high-risk group were to cell adhesion and membrane, and the hypomethylated genes to cell adhesion. Increasing methylation level in FIGO-grade 3 cancers was significantly (P < 0.01) associated with advanced tumor stage for CpG sites located in the TBX2, CHST11, LRP5, and CIZ1/ DNM1 genes.

Conclusion: Our study identified specific DNA methylation signature in low-risk and high-risk endometrial tumors, and potential molecular biomarker genes associated with unfavorable clinical predictive and prognostic factors.

Place, publisher, year, edition, pages
2018.
National Category
Cancer and Oncology
Identifiers
URN: urn:nbn:se:oru:diva-67262OAI: oai:DiVA.org:oru-67262DiVA, id: diva2:1218605
Conference
AMP Europé 2018, Rotterdam, Netherlands, April 30-May 2, 2018
Available from: 2018-06-14 Created: 2018-06-14 Last updated: 2018-06-14Bibliographically approved

Open Access in DiVA

No full text in DiVA

Authority records BETA

Farkas, Sanja A.

Search in DiVA

By author/editor
Farkas, Sanja A.
By organisation
Örebro UniversityÖrebro University Hospital
Cancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar

urn-nbn

Altmetric score

urn-nbn
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf